CSIMarket
 
Crispr Therapeutics Ag  (CRSP)
Other Ticker:  
 
 

Crispr Therapeutics Ag Cash flow Statement Quarterly

CRSP



Select the Financial Report:   Period:   Fiscal Year:



Cash flow Statement
(Quarterly, GAAP in millions $)

(Sep 30 2023)
9 Months
(Jun 30 2023)
6 Months
(Mar 31 2023)
3 Months
(Dec 31 2022)
12 Months
(Sep 30 2022)
9 Months
Income -242.96 -130.81 -53.07 -650.18 -539.60
Depreciation & amortization 14.94 10.01 5.05 24.17 18.33
Amortization of Other Assets - - - - -
Increase (Decrease) in Deferred Revenue - - - - -
Restructuring & Impairment Charges - - - - -
Provision for Loan, Lease, and Other Losses - - - - -
Inventories Decrease /-Increase - - - - -
R & D, Environmental and Other Expense - - - - -
Gain (Loss) on Disposition of Assets - - - - -
Share-based Compensation 62.61 42.64 20.88 97.95 75.14
Income (Loss) from Equity Method Investments - - - - -
Foreign Currency Transaction Gain (Loss), Unrealized - - - - -
Income Loss From Equity Method Investments And Investment Compensation Expense - - - - -
Increase Decrease In Contract With Customer Liability 7.00 - - -0.76 -1.01
Non Cash Expense Related To Collaboration Agreement - - - - -
Acquired In Process Research And Development 2.50 1.50 - - -
Income taxes - - - - -
Losses/ -gains on Investments net - - - - -
Increase (Decrease) in Accounts Receivable - -70.00 - 0.31 0.26
Increase (Decrease) in Accounts Payable and Accrued Liabilities -11.06 13.64 25.21 5.16 36.26
Accrued Expense - - - - -
Deferred Revenue and Customer Advances and Deposits - - - - -
Increase (Decrease) in Prepaid Expense and Other Assets 16.77 15.95 12.04 1.60 7.06
Other Working Capital -0.60 -0.49 -0.17 -1.52 -2.18
Other Noncash Income (Expense) -11.78 -5.62 -0.97 12.47 12.25
Other net - - - - -
Payments for (Proceeds from) Other Operating Activities -1.73 -1.28 -0.18 15.31 10.83
Discontinued operations - - - - -
Net Cash flow from Operating Activities -164.30 -124.45 8.80 -495.74 -382.41
Capital Expenditures -8.73 -6.61 -3.06 -37.19 -31.00
Sale of Capital Items - - - - -
Proceeds from Sale and Maturity of Marketable Securities 1,165.09 795.23 386.52 1,196.33 871.28
Payments to Acquire Marketable Securities -697.76 -452.36 -265.63 -1,417.80 -923.40
Real Estate Investments - - - - -
Proceeds From Contribution Of Intellectual Property To Equity Method Investee - - - - -
Net Cash And Restricted Cash Received In Connection With Acquisition Of Controlling Interest - - - - -
Increase (Decrease) in Restricted Cash - - - - -
Payments for (Proceeds from) Loans - - - - -
Payments for (Proceeds from) Deposits - - - - -
Payments for (Proceeds from) Other Investments - - - - -
Payments for (Proceeds from) Federal Reserve and Federal Home Loan Bank - - - - -
Payments to Acquire in Process Research and Development -2.50 -1.50 - - -
Payments to Acquire Equity Method Investments - - - - -
Sale of businesses - - - - -
Accounts payable - - - - -
Receivables - - - - -
Payments for (Proceeds from) Other Investing Activities - - - - -
Other Net 0.00 0.00 0.00 0.00 0.00
Discontinued operations - - - - -
Net Cash flow from Investing Activities 456.10 334.75 117.83 -258.66 -83.12
Short-term debt Net - - - - -
Other borrowing transactions - - - - -
Long-term debt - borrowings - - - - -
Long-term debt - repayments - - - - -
Federal Home Loan Bank and Federal Funds - - - - -
Issuances/ -repurchases of Comm. Stock 23.73 22.17 5.40 38.59 36.11
Partnership and Parent Transactions - - - - -
Issuances/ -repurchases of Pref. Stock - - - - -
Deposits, Annuities, Contract Holders Funds - - - - -
Other financing activities net - - - - -
Other net -0.75 -1.03 -2.66 -2.12 -4.92
Proceeds From Issuance Of Restricted Shares - - - - -
Capital Expenditures Incurred But Not Yet Paid 0.75 1.03 2.66 4.92 5.02
Debt Conversion Converted Instrument Amount - - - - -
Noncash Contribution Of Intellectual Property To Equity Method Investee - - - - -
Issuance Costs For Initial Public Offering In Accounts Payable And Accrued Expenses - - - - -
Payments of Dividends, Preferred Stock and Preference Stock - - - - -
Dividends paid - - - - -
Net Cash flow from Financing Activities 23.73 22.17 5.40 38.59 36.11
Effect of exchange rate on cash flow 0.01 0.06 0.03 -0.08 -0.20
Discontinued operations - - - - -
Free Cash Flow -173.03 -131.06 5.74 -532.93 -413.41
Total Cash Flow 315.54 232.54 132.06 -715.88 -429.62
Cash & cash equiv. at beg. of the Year - - - - -
Cash & cash equivalents at end of period - - - - -
Cash Interests paid - - - - -
Cash Income taxes paid - - - - -




Untitled Document





	
	


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com